Article Sidebar

PDF
Date Published: 05/07/2023
Abstract Views: 1586
Views PDF: 253
DOI: https://doi.org/10.51298/vmj.v527i2.5886
Issue
Vol. 527 No. 2 (2023)
Section
Các bài báo
How to Cite
Nguyễn, T. T. H., Nguyễn, V. H., & Trần, T. (2023). EVALUATION OF THE SAFETY OF ADJUVANT XELOX REGIMEN FOR STAGES III COLON CANCER AT K HOSPITAL AND HA NOI MEDICAL UNIVERSITY HOSPITAL. Vietnam Medical Journal, 527(2). https://doi.org/10.51298/vmj.v527i2.5886

EVALUATION OF THE SAFETY OF ADJUVANT XELOX REGIMEN FOR STAGES III COLON CANCER AT K HOSPITAL AND HA NOI MEDICAL UNIVERSITY HOSPITAL

Thị Thúy Hằng Nguyễn1, Văn Huy Nguyễn2, Thắng Trần2,
1 K hospital
2 K hospital

Main Article Content

Abstract

Objective: Evaluation of the safety of adjuvant XELOX regimens in stage III coloncancer patients at K Hospital and Ha Noi Medical Univesity Hospital. Methods: This retrospective descriptive study analyzed. 70stage III colon cancer patients were treated with adjuvant XELOX regimens. Side effects ofchemotherapy regimens were identified. Results:70 patients were enrolled in the trial. The rate of hematologic and non-hematologic adverse effects was low and mostly grade 1 and 2 including anemia, leukopenia, thrombocytopenia. These percentages were 20 %, 41.3%, 5.7%, respectively. Leukopenia was common in 4 cycle. 90% of patients with grade 4 leukopenia had clinical infection. The rate of peripheral neurotoxity was 52.5%. Conclusion: Adjuvant XELOX regimens for stage III colon cancer patients was a safe modality.

Article Details

Keywords

Stage III colon cancer, XELOX regimen, Side effects

References

1. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356-387. doi:10.1016/j.ejca.2018.07.005
2. M.B Amin et al. Colon and Rectum. In: AJCC Cancer Staging Manual, Eight Edition. ; 2017:251-274.
3. Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. Accessed September 20, 2020. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#c tc_50.
4. Lu G chun, Fang F, Li D chuan. [Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer]. Zhonghua Zhong Liu Za Zhi. 2010;32(2):152-155.
5. Lee SI, Park SH, Lim DH, et al. A Retrospective Study of First-Line Combination Chemotherapy in Advanced Colorectal Cancer: A Korean Single-Center Experience. Cancer Res Treat. 2011;43(2):96-101. doi:10.4143/crt.2011.43.2.96
6. Diao C, Cheng RC, Zhang JM, et al. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer]. Zhonghua Zhong Liu Za Zhi. 2008;30(2):147-150.
7. Tyagi P, Grothey A. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial. Clin Colorectal Cancer. 2006;6(4):261-264. doi:10.3816/CCC.2006.n.044
8. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011; 29 (11):1465-1471. doi:10.1200/JCO.2010.33.6297
9. Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients. JCO. 2007; 25(1):102-109. doi:10.1200/ JCO.2006.08.1075
10. Argyriou AA, Velasco R, Briani C, et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Annals of Oncology. 2012;23(12):3116-3122. doi:10.1093/ annonc/mds208